Novel Combinatorial Therapeutic Strategy to Overcome Gain-of-Function p53 Mutations

Abstract excerpt

Mutations in the “guardian of the genome” TP53 predominate in solid tumors. In addition to loss of tumor suppressor activity, a specific subset of missense mutations confers additional oncogenic properties. These “gain-of-function” (GOF) mutations portend poor prognosis across cancer types regardless of treatment. Our objective in this study was to identify novel therapeutic opportunities t...

Topics

Open a Topic to create a Post that cites this publication.

• Cancer-related Molecular Pathways
• Genetic Therapy
• Hippo pathway signaling and YAP/TAZ
• Molecular Targeted Therapy
• Mutation
• Neoplasms
• Tumor Suppressor Protein p53
• Ubiquitin and proteasome pathways

Identifiers and source

Literature Corpus work

e5542039-d37b-5747-b1be-6b71bd22ba28

DOI

10.20944/preprints201805.0088.v1